1. Home
  2. Live Updates
  3. Biomarker data

Live Breaking News & Updates on Biomarker data

Stay informed with the latest breaking news from Biomarker data on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Biomarker data and stay connected to the pulse of your community

Biomarker Data and Patient Preference Inform Perioperative Therapy Selection in Early HER2+ Breast Cancer

Maria Hafez, MD, discusses factors such as HER2 status, lymph node negativity, and risk stratification that influence the selection of adjuvant treatment approaches for patients with early-stage HER2-positive breast cancer and expands on pivotal data that have changed the paradigm.

Philadelphia , Pennsylvania , United-states , Maria-hafez , Sidney-kimmel-medical-college , Science-summit , Breast-cancer-clinical-research , Sidney-kimmel-cancer-center , Thomas-jefferson-university , Biomarker-data , Perioperative-therapy , Her2-breast-cancer

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

Biomarker Data from Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis (MF) Suggestive of Disease Modification

Australia , Germany , China , Austria , Boston , Massachusetts , United-states , Canada , Israel , United-kingdom , Singapore , Hong-kong

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Milan , Lombardia , Italy , Irina-koffler , Paul-spencer , Tiziana-life-sciences-ltd , Research-in-multiple-sclerosis , Research-of-multiple-sclerosis , Nasdaq , Business-development , Tiziana-life-sciences , Lifesci-advisors

Passage Bio, Inc. (NASDAQ:PASG) Q4 2022 Earnings Call Transcript

Operator: Good morning, and welcome to the Passage Bio Fourth Quarter and Full Year 2022 Financial Operating Results Conference Call. At this time, all participants are in listen-only mode.

Brendan-smith , Yaron-werber , Madhu-kumar , Simona-king , Stuart-henderson , Mark-forman , Omari-baruti , Most-valuable-golf-companies , Corporate-development , Goldman-sachs , High-growth-semiconductor-stocks-that-are-profitable

Cassava Sciences, Inc. Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimer's disease dementia. This was an open-label safety study with exploratory... | January 25, 2023

New-york , United-states , Puerto-rico , Australia , Canada , South-korea , Suzanne-hendrix , City-university-of-new-york , Cassava-sciences-inc , Pentara-corporation , Cassava-sciences , Drug-administration

Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma




Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma

GlobeNewswire

December 12, 2022



Updated Results from CHARIOT Phase 2 trial presented at the 2022 ASH Annual Meeting indicate a 73.3% overall response rate and 60% complete...

United-states , Texas , Singapore , American , Ivan-horak , Sairah-ahmed , Dave-schemelia , Davidm-kurtz , Wilsonw-cheung , Tessa-therapeutics-ltd , University-of-texas-md-anderson-cancer-center , Drug-administration

Anna Berry, Author at MedCity News

Anna Berry, Author at MedCity News
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.

Sweden , Swedish , Anna-berry , Swedish-cancer-institute-in-seattle , Laboratory-medicine-at-syapse , University-of-nebraska-medical-center , Personalized-medicine-program , University-of-california-san-francisco , Senior-vice-president , Biomarker-data , Laboratory-medicine , Deputy-director

Presentation of Biomarker Data at AACR

Faron Pharmaceuticals Ltd ("Faron or Company") Faron Announces Upcoming Presentation of Biomarker Analysis from Patients in MATINS Trial at AACR Annual Meeting...

Boston , Massachusetts , United-states , Finland , Jukka , Lapland , American , David-daley , Petri-bono , Markku-jalkanen , Sandy-jamieson , Lindsey-neville

Presentation of Biomarker Data at AACR

Faron Pharmaceuticals Ltd ("Faron or Company") Faron Announces Upcoming Presentation of Biomarker Analysis from Patients in MATINS Trial at AACR Annual Meeting...

Boston , Massachusetts , United-states , Finland , Jukka , Lapland , American , David-daley , Petri-bono , Markku-jalkanen , Sandy-jamieson , Lindsey-neville

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022

/PRNewswire/ -- RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels Dose-dependent...

Brazil , Roberto-giugliani , Porto-alegre , Dana-cormack , Chris-brinzey , Steve-pakola , Technology-platform , Technology-platform-licensees , Drug-administration , Nasdaq , Exchange-commission , Corporate-communications